• Jorge Garcia Borrega, Michael von Bergwelt-Baildon, and Boris Böll.
• Universität zu Köln, Klinik I für Innere Medizin, Centrum für Integrierte Onkologie Aachen Bonn Köln Düsseldorf; Hämatologie-Onkologie, Internistische Intensivmedizin, Köln, Deutschland.
• Dtsch. Med. Wochenschr. 2019 Dec 1; 144 (24): 1703-1708.

AbstractCAR T-cell treatment has brought a significant benefit for patients with relapsed and refractory lymphoma and even long lasting remissions seem to be possible. Despite the good results CAR T-cell treatment is associated with severe and potentially life-threatening adverse effects. Patients regularly develop Cytokine Release Syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) after the transfusion of CAR T-cells. In addition to these immunological reactions patients can develop severe and life-threatening infections and other related adverse effects. Due to the increasing number of patients receiving CAR T-cells and the upcoming clinical trials more and more patients will potentially require intensive care treatment for the adverse effects after CAR T-cell treatment. The management of these patients requires an extensive diagnostic workup and complex treatment. An interdisciplinary team of hematologist, intensivist and others like neurologist and palliative medicine consultants is crucial for the best treatment of these patients. Together with the increasing number of patients this can lead to logistical issues for the intensive care departments of centers offering CAR T-cell therapies.© Georg Thieme Verlag KG Stuttgart · New York.

13 keywords...

hide…